Abstract
Scope:
The aim of the present work was to determine new biomarkers of the biological effects of hesperidin in orange juice (OJ) applying a nontargeted metabolomics approach validated by targeted metabolomics analyses of compliance biomarkers.
Methods and results:
Plasma/serum and urine targeted (HPLC-MS/MS) and untargeted (1 H-NMR) metabolomics signatures were explored in a subsample with pre- and stage-1 hypertension subjects of the CITRUS study (N = 159). Volunteers received 500 mL/day of control drink, OJ, or hesperidin-enriched OJ (EOJ) for 12-weeks. A 6-h postprandrial study was performed at baseline. Targeted analyses revealed plasma and urine hesperetin 7-O-β-D-glucuronide as the only metabolite differing between OJ and EOJ groups after 12-weeks consumption, and in urine is correlated with a decreased systolic blood pressure level. The nontargeted approach showed that after single dose and12-weeks consumption of OJ and EOJ changed several metabolites related with an anti-inflammatory and antioxidant actions, lower blood pressure levels and uraemic toxins.
Conclusions:
Hesperetin 7-O-β-D-glucuronide could be a candidate marker for distinguishing between the consumption of different hesperidin doses at 12-weeks consumption as well as a potential agent mediating blood pressure reduction. Moreover, changes in different endogenous metabolites could explain the mechanisms of action and the biological effects of hesperidin consumption. This article is protected by copyright. All rights reserved.
Full text
